<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="132905">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02030678</url>
  </required_header>
  <id_info>
    <org_study_id>STao</org_study_id>
    <nct_id>NCT02030678</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Second-line Irinotecan Hydrochloride in Metastatic Breast Cancer.</brief_title>
  <official_title>Phase II Study of Second-line Irinotecan Hydrochloride in Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Liaoning Tumor Hospital &amp; Institute</source>
  <oversight_info>
    <authority>China: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phaseII trial of second-line irinotecan  Hydrochloride  in Metastatic Breast Cancer.
      Evaluate the effect and safety of  irinotecan  Hydrochloride  in Metastatic breast cancer
      patients whose disease recurrent after using anthracycline or taxane drugs. The endpoint is
      Disease Control Rate and Progression free survival. The second endpoint is Adverse Events
      and Sever Adverse Events.The duration of irinotecan is at least 3 cycles(61 days), till dead
      or .
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The endpoint is Disease Control Rate  and Progression free survival. The second endpoint is
      Adverse Events and Sever Adverse Events.The duration of Iriontecan is at least 3 cycles(61
      days), till dead or Progressive Disease.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>3cycles (21days/cycle)</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Disease Control Rate:Completely Response+Partial Response+Stable Disease</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>irinotecan Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>irinotecan Hydrochloride, at least 3cycels or till Progressive Disease or death</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan  Hydrochloride</intervention_name>
    <description>irinotecan  Hydrochloride, 350mg/m2,at least 3cycles,21days/cycle.</description>
    <arm_group_label>irinotecan Hydrochloride</arm_group_label>
    <other_name>Kaiputuo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mestatic breast cancer patients whose disease recurrent after using anthracycline or
             taxane drugs

        Exclusion Criteria:

          -  Heart Disease.etc
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tao Sun, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Liaoning Tumor Hospital &amp; Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tao Sun, Doctor</last_name>
    <email>jianong@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SunTao</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tao Sun, Doctor</last_name>
      <email>jianong@126.com</email>
    </contact>
    <investigator>
      <last_name>Tao Sun, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 7, 2014</lastchanged_date>
  <firstreceived_date>January 7, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Liaoning Tumor Hospital &amp; Institute</investigator_affiliation>
    <investigator_full_name>Sun Tao</investigator_full_name>
    <investigator_title>Director of Oncology</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
